In Hurricane Ida’s Wake, HRSA Announces 340B Registration Flexibility in Louisiana and Mississippi

In light of Hurricane Ida, Louisiana and Mississippi health care providers eligible to participate in the 340B program may enroll immediately rather than having to wait until the next quarterly registration period Oct. 1 through 15.

Louisiana and Mississippi health care providers eligible to participate in the 340B program may enroll immediately rather than having to wait until the next quarterly registration period Oct. 1 through 15, the U.S. Health Resources and Services Administration (HRSA) announced

Read More »

HRSA Veteran Herzog to Oversee 340B Program as Agency Begins Search for New OPA Director

Michelle Herzog, the new acting director of HRSA's 340B drug pricing program, speaks at the 2015 340B Coalition summer conference.

Michelle Herzog, long-time second-in-command at the U.S Health Resources and Services Administration’s Office of Pharmacy Affairs (OPA), has taken charge as OPA director on an acting basis.

A HRSA spokesperson confirmed yesterday morning that Herzog will oversee OPA temporarily now

Read More »

Breaking News

News Alert: Becerra Signs off on HRSA Reorganization that Elevates 340B Program’s Status

HHS Secretary Xavier Becerra has signed off on a reorganization of HRSA that elevates decision making about the 340B program closer to the top of the department.

The 340B drug pricing program has a new, higher profile home within the U.S. Health Resources and Services Administration (HRSA), and likely is getting a new director due to its current director’s promotion.

U.S. Health and Human Services (HHS) Secretary

Read More »

Biden Wants to Rescind Trump’s Most Favored Nation Proposal That Received Widespread Criticism from Drug Industry and 340B Providers

The Biden administration plans to rescind ex-President Trump's Most Favored Nation interim final rule that would peg Medicare reimbursement for some drugs to the lowest price that drug manufacturers get in similar countries.

The Biden administration plans to rescind a published but unimplemented Trump-era regulation that would peg Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers get in similar countries. The widely criticized regulation

Read More »

In Fight with National Implications, Calif. 340B Providers Try to Stop Move That Could Result in Millions of Lost Savings

California Gov. Gavin Newsom's twice-delayed executive order that would slash Medicaid reimbursement for 340B-purchased drugs is back on track.

California’s twice-postponed shift of Medicaid (Medi-Cal) managed care prescription drug benefits to Medi-Cal fee for service (FFS) is back on for Jan. 1, 2022, one year later than originally planned.

A similar high-stakes battle over Medicaid reimbursement for 340B-purchased drugs

Read More »

HRSA Posts Novartis Notice About 340B Refunds on a Top-Selling Drug—With Contract Pharmacy Strings Attached (Updated)

Novartis exempted Mississippi 340B providers from its contract pharmacy restrictions following a new state law.

UPDATE Tuesday, July 27, 2021, 1:45 p.m. Eastern—Drug manufacturer Novartis provided the following statement:

“Novartis recently notified the Health Resources and Services Administration (HRSA) that we inadvertently neglected to offer the 340B ceiling price to covered entity types added by

Read More »

For 340B Hospitals, Some Consolation in Otherwise Disappointing CMS Drug Reimbursement Rule

CMS proposes extending "pass-through" status for 24 drugs and three biosimilars in 2022—a move that would temporarily shield the medicines from the deep payment cut for 340B hospitals.

Hospitals groups were deeply disappointed last week with the U.S. Centers for Medicare & Medicaid Services’ (CMS) proposal to continue a nearly 30% cut in Medicare Part B reimbursement for hospitals’ 340B purchased drugs in place since 2018.

Another provision

Read More »

Pedley Provides 340B Update but Avoids Contract Pharmacy Controversy

Due to litigation, 340B program director Rear Adm. Krista Pedley could say little about the drug discount program during yesterday’s 340B Coalition virtual summer conference.

Rear Adm. Krista Pedley, Director of the U.S. Health Resources and Services Administration’s (HRSA) Office of Pharmacy Affairs (OPA), gave a brief update on the 340B program during yesterday’s 340B Coalition virtual summer conference. She explained that “due to current

Read More »

340B Program Flexibilities to Continue As COVID-19 Emergency Extended

HHS Secretary Xavier Becerra this week extended the COVID-19 public health emergency until mid-October.

U.S. Health and Human Services (HHS) Secretary Xavier Becerra on Monday extended the COVID-19 national public health emergency (PHE) for another 90 days, to Oct. 17. The move extends 340B program flexibilities implemented during the pandemic’s early days.

In

Read More »

With 340B Hospital Recertification Set to Begin Soon, HRSA To Host Webinar Aug. 11

Annual recertification of hospital eligibility for 340B drug discounts begins on Aug. 16.

The recertification period for hospitals to continue to participate in the 340B program begins in mid-August. The U.S. Health Resources Services Administration (HRSA) has scheduled an informational webinar on Wednesday, Aug. 11 at 1 p.m. Eastern time to discuss the

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live